• Je něco špatně v tomto záznamu ?

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

C. Pott, V. Jurinovic, J. Trotman, B. Kehden, M. Unterhalt, M. Herold, RV. Jagt, A. Janssens, M. Kneba, J. Mayer, M. Young, C. Schmidt, A. Knapp, T. Nielsen, H. Brown, N. Spielewoy, C. Harbron, A. Bottos, K. Mundt, R. Marcus, W. Hiddemann, E. Hoster

. 2024 ; 42 (5) : 550-561. [pub] 20231214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007165

PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. RESULTS: MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. CONCLUSION: MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007165
003      
CZ-PrNML
005      
20240423155747.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.23.00838 $2 doi
035    __
$a (PubMed)38096461
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pott, Christiane $u University Hospital Schleswig-Holstein, Kiel, Germany $1 https://orcid.org/0009000592608340
245    10
$a Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study / $c C. Pott, V. Jurinovic, J. Trotman, B. Kehden, M. Unterhalt, M. Herold, RV. Jagt, A. Janssens, M. Kneba, J. Mayer, M. Young, C. Schmidt, A. Knapp, T. Nielsen, H. Brown, N. Spielewoy, C. Harbron, A. Bottos, K. Mundt, R. Marcus, W. Hiddemann, E. Hoster
520    9_
$a PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders. MRD status was assessed at predefined time points (mid-induction [MI], end of induction [EOI], and at 4-6 monthly intervals during maintenance and follow-up). Patients with evaluable biomarker data at diagnosis were included in the survival analysis. RESULTS: MRD positivity was associated with inferior progression-free survival (PFS) at MI (hazard ratio [HR], 3.03 [95% CI, 2.07 to 4.45]; P < .0001) and EOI (HR, 2.25 [95% CI, 1.53 to 3.32]; P < .0001). MRD response was higher after G- versus R-chemotherapy at MI (94.2% v 88.9%; P = .013) and at EOI (93.1% v 86.7%; P = .0077). Late responders (MI-positive/EOI-negative) had a significantly poorer PFS than early responders (MI-negative/EOI-negative; HR, 3.11 [95% CI, 1.75 to 5.52]; P = .00011). The smallest proportion of MRD positivity was observed in patients receiving bendamustine at MI (4.8% v 16.0% in those receiving CHOP; P < .0001). G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-CVP, 21.7% v G-CVP, 9.4%). Throughout maintenance, MRD positivity was associated with clinical relapse. CONCLUSION: MRD status can determine outcome after induction and during maintenance, and MRD negativity is a prerequisite for long-term disease control in FL. The higher MRD responses after G- versus R-based treatment confirm more effective tumor cell clearance.
650    _2
$a lidé $7 D006801
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a bendamustin hydrochlorid $7 D000069461
650    _2
$a cyklofosfamid $7 D003520
650    _2
$a doxorubicin $7 D004317
650    12
$a galium $x terapeutické užití $7 D005708
650    12
$a folikulární lymfom $7 D008224
650    _2
$a reziduální nádor $x farmakoterapie $7 D018365
650    _2
$a prednison $7 D011241
650    _2
$a rituximab $7 D000069283
650    _2
$a vinkristin $7 D014750
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Jurinovic, Vindi $u Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany $u Institute for Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany
700    1_
$a Trotman, Judith $u Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia $1 https://orcid.org/0000000180094593
700    1_
$a Kehden, Britta $u University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Unterhalt, Michael $u Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany
700    1_
$a Herold, Michael $u HELIOS Klinikum, Erfurt, Germany $1 https://orcid.org/0000000268013292
700    1_
$a Jagt, Richard van der $u University of Ottawa, Ottawa Hospital, Ottawa, ON, Canada $1 https://orcid.org/0000000157060109
700    1_
$a Janssens, Ann $u University Hospitals Leuven, Leuven, Belgium
700    1_
$a Kneba, Michael $u University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Mayer, Jiri $u University Hospital and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000305679887
700    1_
$a Young, Moya $u East Kent Hospital, Canterbury, United Kingdom
700    1_
$a Schmidt, Christian $u Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany
700    1_
$a Knapp, Andrea $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Nielsen, Tina $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Brown, Helen $u Roche Products Ltd, Welwyn Garden City, United Kingdom $1 https://orcid.org/000900073637891X
700    1_
$a Spielewoy, Nathalie $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Harbron, Chris $u Roche Products Ltd, Welwyn Garden City, United Kingdom
700    1_
$a Bottos, Alessia $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Mundt, Kirsten $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Marcus, Robert $u Kings College Hospital, London, United Kingdom
700    1_
$a Hiddemann, Wolfgang $u Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany
700    1_
$a Hoster, Eva $u Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany $u Institute for Medical Information Processing, Biometry, and Epidemiology, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany $1 https://orcid.org/0000000207491389
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 42, č. 5 (2024), s. 550-561
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38096461 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155743 $b ABA008
999    __
$a ok $b bmc $g 2081258 $s 1216932
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 42 $c 5 $d 550-561 $e 20231214 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace